4.5 Article

Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles

期刊

VACCINE
卷 30, 期 35, 页码 5206-5214

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.06.011

关键词

RSV fusion protein; Protection; Polyphosphazene microparticles

资金

  1. Krembil Foundation
  2. Canadian Institutes of Health Research (CIHR)
  3. Bill and Melinda Gates Foundation

向作者/读者索取更多资源

Although respiratory syncytial virus (RSV) is the leading cause of serious respiratory tract disease in children, to date no RSV vaccine is available. To produce an effective subunit vaccine, a truncated secreted version of the F protein (Delta F) was expressed in mammalian cells, purified and shown to form trimers. The Delta F protein was then formulated with a CpG oligodeoxynucleotide (ODN) and an innate defense regulator (IDR) peptide in polyphosphazene microparticles (Delta F-MP). Mice immunized either intramuscularly (IM) or intranasally (IN) with Delta F-MP developed significantly higher levels of virus-neutralizing antibodies in the sera and lungs, as well as higher numbers of IFN-gamma secreting cells than mice immunized with the Delta F protein alone. In contrast, the IM delivered Delta F induced high production of IL-5 while the IN delivered Delta F did not elicit a measurable immune response. After RSV challenge, essentially no virus and no evidence of immunopathology were detected in mice immunized with Delta F-MP regardless of the route of delivery. While the mice immunized IM with Delta F alone also showed reduced virus replication, they developed enhanced levels of pulmonary IgE, IL-4, IL-5, IL-13 and eotaxin, as well as eosinophilia after challenge. The level of protection induced by the Delta F-MP formulation was equivalent after IM and IN delivery. The efficacy and safety of the Delta F-MP formulation was confirmed in cotton rats, which also developed enhanced immune responses and were fully protected from RSV challenge after vaccination with Delta F-MP. In conclusion, formulation of recombinant Delta F with CpG ODN and IDR peptide in polyphosphazene microparticles should be considered for further evaluation as a safe and effective vaccine against RSV. (C) 2012 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据